A newly identified set of microRNAs may give scientists fresh insight into how protein levels in the brains of Alzheimer's patients are regulated.
GE Healthcare has at long last nailed down FDA approval for an imaging agent designed to help evaluate living patients for Alzheimer's disease or dementia. It's the second brain-imaging drug of its kind to gain U.S. regulators' OK, and plans call for rolling it out commercially in 2014.
Last year, scientists reported that the drug bexarotene--marketed as Targretin--could rapidly break apart beta amyloid plaque deposits characteristically found in the brains of Alzheimer's patients. But new research suggests those findings may have been too good to be true.
Researchers from Massachusetts General Hospital and Harvard University have discovered a possible new mechanism to halt the disease process in Alzheimer's.
For the first time, scientists have genetically engineered a lab rat that has the full range of brain changes associated with Alzheimer's disease--that is, it more accurately mirrors the brain of a person with the disease.
Close to six years after promising up to $500 million to gain rights to Zurich-based Cytos Biotechnology's ($CYTN) smoking cessation vaccine, Novartis has handed back the rights to the treatment and written off its investment.
Eli Lilly's ($LLY) solanezumab has secured an endorsement from Alzheimer's researchers, who will study the experimental drug as a preventive therapy against the memory-robbing disease in patients before symptoms emerge.
While the cause of Alzheimer's disease continues to elude scientists, a new compound carries the promise of restoring memory loss and reversing the symptoms of the disease.
Scientists in two different studies identified what is now only the second known gene mutation suspected to increase the likelihood of Alzheimer's disease in senior citizens.
In the two pivotal Phase III studies of the drug, investigators determined that there was a noticeable effect on the level of beta amyloid found in patients' blood, suggesting that solanezumab had reduced levels of the toxic protein in the brain.